DEXYANE MeD

Palpebral

Soothes and reduces the reactivity of atopy-prone eyelids. Tested under dermatological control. Medical device

DEXYANE MeD

Palpebral

Treats eczema lesions - Soothes itchiness - Decongests - Soothes Medical device

A medical device that treats atopic or contact eczema on the eyelids.

  • Soothes and reduces the reactivity of sensitive, atopy-prone eyelids
  • Soothes and reduces the reactivity of atopy-prone eyelids. Tested under dermatological control.
Cannula tube

Usable by Infants - Children - Family - Adults

Age From 3 month(s)

Suitable Eyelids

Skin type Eyelid atopy

Need Anti-eczema

Made in France

DEXYANE MED Palpebral is a medical device* for treating localised atopic and/or contact eczema on the eyelids.
Its formula, specially adapted to respect the delicate skin of the eyelids, acts as an ultra-hydrating dressing.
It instantly soothes itching sensations** and reduces burning sensations**.
DEXYANE MED Palpebral restores the skin barrier and corrects dryness.
It can be used as a stand-alone treatment, in combination with, or as a follow-up to topical corticosteroids.
Clinically proven effectiveness.

Benefit

DEXYANE MeD Palpébral soothes and reduces the reactivity of sensitive, atopy-prone eyelids.

Benefits

• SOOTHES itching due to dryness
• COMFORTS immediately and decongests
• REDUCES the reactivity of atopy-prone eyelids

*DEXYANE MED Palpebral is a medical device, a regulated health product which carries, in accordance with this regulation, the CE mark. Carefully read the instruction leaflet provided. Do not use if pregnant or breastfeeding. Avoid direct contact with the eyes. Age 3 months and up. Manufacturer : Pierre Fabre Medicament.
**Result of a clinical study conducted on 33 adults from 19-70 years old with mild to moderate atopic or contact eyelid eczema. DEXYANE MED Palpebral was applied twice a day to the eyelids for 22 days. The clinical severity score (including itching, burning, tightness, etc.) from 0 to 9, immediately after 3 days of application, was compared to the pre-application scores. Immediately, the itching score significantly decreased, and the burning score improved by day 3. The overall development of lesions was evaluated by the PGA score on a 5-point scale : 0 (aggravation) to 4 (completely healed); after 3 days of application, the majority of patients felt an improvement. PFDC study PRM03-F-197_V3_AN. 03/2019. 98-104, 108.

*DEXYANE MED Palpebral is a medical device, a regulated health product which carries, in accordance with this regulation, the CE mark. Carefully read the instruction leaflet provided. Do not use if pregnant or breastfeeding. Avoid direct contact with the eyes. Age 3 months and up. Manufacturer : Pierre Fabre Medicament.

Environmental impact

Formula

Formula rating : B

Biodegradable formula*
85.0% natural origin ingredients
*According to a OECD 301 test or Biodegradability index method

Packaging

Packaging rating : D

Not recyclable packaging

Manufacturing

Manufacturing rating : B

Made and packaged in a factory certified for the environment***
***according to ISO 14001 and/or 50001 standards

Transportation

Transportation rating : D

Societal impact

Societal impact

Societal impact rating : B

Product manufactured and packaged in a factory meeting French social standards
Ducray is a brand of the Pierre Fabre Group, certified at the highest Exemplary level of AFNOR Certification’s Committed to CSR and Responsibility Europe labels, thus consolidating a long-standing commitment to contributing to sustainable development.

Application

Frequency of use

1 to 2 times a day

• Do not use the product if the tube is damaged
• If you experience any side effects as a result of using the product, seek medical advice
• Can be used on skin damaged by cancer treatments|• Apply a thin layer directly on the affected eyelids with a clean finger, avoiding contact with the eye
• For external use
• Use as a stand-alone treatment, in combination with, or as a follow-up to topical corticosteroids
• Once or twice a week
• Do not use if you are allergic to any of the ingredients
• If you experience an allergic reaction, consult a doctor
• Due to a lack of data, use if pregnant or breastfeeding is not recommended
• Keep out of the reach of children
• Avoid direct contact with the eyes
• Close the tube tightly after use
• Do not use the product if the tube is damaged
• If you experience any side effects as a result of using the product, seek medical advice
• Can be used on skin damaged by cancer treatments

• Apply a thin layer directly on the affected eyelids with a clean finger, avoiding contact with the eye
• For external use
• Use as a stand-alone treatment, in combination with, or as a follow-up to topical corticosteroids
• Once or twice a week
• Do not use if you are allergic to any of the ingredients
• If you experience an allergic reaction, consult a doctor
• Due to a lack of data, use if pregnant or breastfeeding is not recommended
• Keep out of the reach of children
• Avoid direct contact with the eyes
• Close the tube tightly after use
• Do not use the product if the tube is damaged
• If you experience any side effects as a result of using the product, seek medical advice
• Can be used on skin damaged by cancer treatments

Ingredients

AQUA. GLYCERIN. CAPRYLIC/CAPRIC TRIGLYCERIDE. BUTYLENE GLYCOL. POLYSORBATE 60. GLYCERYL STEARATE. BUTYROSPERMUM PARKII (SHEA) BUTTER. CERA ALBA. PEG-100 STEARATE. 10-HYDROXYDECENOIC ACID. CAPRYLYL GLYCOL. CETYL ALCOHOL. CITRIC ACID. GLYCYRRHETINIC ACID. GUANIDINE CARBONATE. POLYACRYLATE-13. POLYISOBUTENE. POLYSORBATE 20. SCLEROTIUM GUM. SORBITAN ISOSTEARATE

The consumer is advised to systematically check the composition of the product before purchasing it.

Results

• Immediately¹ after application : itching reduced
• After 3 days¹ : significant improvement and even complete disappearance of clinical signs, particularly burning sensations

    ¹Result of a clinical study conducted on 33 adults from 19-70 years old with mild to moderate atopic or contact eyelid eczema. DEXYANE MED Palpebral was applied twice a day to the eyelids for 22 days. The clinical severity score (including itching, burning, tightness, etc.) from 0 to 9, immediately after 3 days of application, was compared to the pre-application scores. Immediately, the itching score significantly decreased, and the burning score improved by day 3. The overall development of lesions was evaluated by the PGA score on a 5-point scale : 0 (aggravation) to 4 (completely healed); after 3 days of application, the majority of patients felt an improvement. PFDC study PRM03-F-197_V3_AN. 03/2019. 98-104, 108.
    Loading...